Pharmaceuticals

The Indian pharmaceutical industry valued at US$ 12 billion has portrayed tremendous progress with reference to infrastructure development, technology base creation and range of production. The domestic market in India is estimated to be at US$ 12 billion by 2010.

The advantages that India offers in this industry:

• Knowledge based industry.
• Large manufacturing base for high quality drugs and formulations.
• Developing cost effective technologies for drug intermediaries and bulk actives without a compromise on quality.
• Cost advantage in terms of drug production.
• Maintenance of high standards in terms of purity, stability and International Safety, Health and Environment protection.
• Tremendous export potential.
• Strong scientific and technical manpower.
• World class national laboratories in process development.
• Increasing balance of trade in the sector.
• An excellent centre for clinical trials.

Foreign Direct Investments:

• FDI up to 74 % in the case of bulk drugs, their intermediate pharmaceuticals and formulations (except those produces by use of recombinant DNA technology) would be covered under the automatic route.
• FDI above 74 % for manufacture of bulk drugs will be considered by the government on case to case basis.

Source: Ministry of External Affairs: INDIA , Dynamic Business Partner: Investor Friendly Destination